到目前为止,还没有任何类型的mRNA疫苗被批准用于人类,但基于他在20世纪80年代和90年代研究艾滋病疗法的经验,福奇相信这项针对新冠病毒的技术前景明朗。
“For some reason that we're still struggling with, the body does not make an adequate immune response to HIV,” he says. To fight off that virus, a vaccine has to work better than the body’s own natural response. By contrast, “it's obvious that many people make a very adequate immune response” to the SARS-CoV-2 virus, and the animal trials so far show that modest doses of the mRNA vaccine for coronavirus have also generated a strong immune response.
他说:“由于某些一直让我们不解的原因,人体无法对艾滋病毒做出充分的免疫反应。”为了对抗这种病毒,疫苗必须比人体自身的自然反应更有效。相比之下,“很明显,许多人对新冠病毒做出了非常充分的免疫反应”,而迄今为止的动物试验表明,适量的新冠病毒mRNA疫苗也产生了强烈的免疫反应。
He adds that NIAID is still developing and supporting multiple vaccine efforts, in case those that go into trials soonest don’t ultimately prove safe and effective. “You want a lot of shots on goal. We want four or five candidates that we put out there all within a reasonable time,” he says.
他补充说,美国国家过敏症及传染病研究所仍在研发和支持多种疫苗,以防那些最快进入试验的疫苗最终被证明不安全和无效。“你需要很多尝试的机会。我们希望在合理的时间内推出4到5种备选疫苗。”
【福奇:没有科学证据表明新冠病毒来自中国实验室】相关文章:
★ 从现在开始行动吧
最新
2020-09-15
2020-09-15
2020-09-15
2020-09-15
2020-09-15
2020-09-15